Irwin, D.

(David Irwin)

patient bortezomib myeloma response dexamethasone therapy study treatment survival trial analysis journal richardson signi ﬁcantly signi month response rate high-dose subgroups score high-dose dexamethasone phase result blood british journal ef ﬁcacy cancer disease bortezomib arm bene ﬁt metaphase cytogenetics apex trial quality dexamethasone arm impairment myeloma patients research cytogenetic ﬁcantly progression impact population cycle baseline transplantation method ﬁcacy haematology dexamethasone patients british prognostic difference metaphase england journal table blade cell transplantation analyses cohort johnson anderson bortezomib patients ﬁcant barlogie b number death subgroup facon assessment publishing incidence blackwell phase 2 study 5- week cycles author safety marrow chromosome comparison reduction

7 Most Recent Publications

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma (Article) Vogl, D.T. Stadtmauer, E.A. Anderson, K.C. Richardson, P.G. Sonneveld, P. Schuster, M.W. Irwin, D. Facon, T. Harousseau, J-L. Boral, A.L. Neuwirth, R.	2009-11-01
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: Results from the APEX study (Article) Lee, S.J. Richardson, P.G. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. San Miguel, J-F. Crawford, B.T. Massaro, J. Dhawan, R. Gupta, S.	2008-11-01
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (Article) Niesvizky, R. Richardson, P.G. Harousseau, J-L. Boral, A.L. Esseltine, D-L. Anderson, K.C. Bladé, J. Rajkumar, S.V. Coleman, M. Rosiñol, L. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T.	2008-10-01
Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study (Article) San Miguel, J-F. Richardson, P.G. Goldschmidt, H. Reece, D. Bladé, J. Boccadoro, M. Cavenagh, J. Neuwirth, R. Boral, A.L. Esseltine, D-L. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S.	2008-04-01
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial (Article) Richardson, P.G. Sonneveld, P. Reece, D. San Miguel, J-F. Bladé, J. Boccadoro, M. Cavenagh, J. Alsina, M. Rajkumar, S.V. Lacy, M. Jakubowiak, A.J. Dalton, W. Schuster, M.W. Boral, A.L. Esseltine, D-L. Schenkein, D. Anderson, K.C. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H.	2007-11-15
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma (Article) Richardson, P.G. Sonneveld, P. Cavenagh, J. Anderson, K.C. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. San Miguel, J-F.	2007-06-01
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (Article) Jagannath, S. Richardson, P.G. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Cowan, J.M. Anderson, K.C.	2007-01-01

Message*:
Your Email Adress*:
	*: Required fields, please provide an email address so that the RePub team can contact you if needed.